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Abstract
Background: The currently approved therapies fail in a substantial number of colorectal cancer (CRC) patients due
to the molecular heterogeneity of CRC, hence new efficient drug combinations are urgently needed. Emerging data
indicate that 5-azanucleosides are able to sensitize cancer cells to the standard chemotherapeutic agents and
contribute to overcoming intrinsic or acquired chemoresistance.
Methods: CRC cells with different genetic backgrounds (HCT116, DLD-1, HT-29) were sequentially treated with 5-
azanucleosides and topoisomerase inhibitors. The combined effects of these two drug classes on cell viability,
apoptosis, signaling pathways, and colony formation were investigated.
Results: Here, we demonstrate that pretreatment with DNA demethylating agents, 5-aza-2′-deoxycytidine and 5-
azacytidine, sensitizes CRC cells to topoisomerase inhibitors (irinotecan, etoposide, doxorubicin, mitoxantrone),
reducing cell viability and clonogenicity and increasing programmed cell death more effectively than individual
compounds at the same or even higher concentrations. 5-Azanucleosides did not cause considerable immediate
toxic effects as evaluated by analysis of cell viability, apoptosis, DNA damage (γH2A.X), and endoplasmic reticulum
(ER) stress (CHOP). However, 5-azanucleosides exerted long-lasting effects, reducing cell viability, changing cell
morphology, and affecting phosphoinositide 3-kinase (PI3-kinase)/Akt signaling pathway. We found that a single
exposure to 5-azanucleosides is sufficient to induce long-lasting sensitization to topoisomerase inhibitors. The
combinatorial, but not separate, treatment with low doses of 5-aza-2′-deoxycytidine (0.1 μM) and etoposide (0.5 μM)
caused a long-lasting (almost 70 days) reduction in clonogenic/replating ability of DLD-1 cells.
Conclusions: These results suggest that sequential treatments with DNA demethylating agents and topoisomerase
inhibitors may exert clinically relevant anticancer effects.
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Background
Colorectal cancer (CRC) was the third most common
cancer worldwide with 1.36 million new cases and nearly
0.7 million deaths in 2012 [1]. Currently, 5-fluorouracil,
irinotecan (also known as CPT-11), and oxaliplatin con-
stitute the backbone of chemotherapy for CRC. Unfortu-
nately, the molecular heterogeneity of CRC creates the
considerable variability in response to treatment among
patients with the same disease stage. Because the cur-
rently approved therapies fail in a substantial number of
CRC patients, new efficient drug combinations are con-
stantly being sought.
It is now well established that genetic mutations co-
operate with epigenetic changes to drive the formation
and progression of normal colorectal epithelium into
adenocarcinomas. Abnormalities in DNA methylation
occur early in cancer progression, even before the ap-
pearance of the aberrant crypt foci (ACF), the first neo-
plastic lesions identified in CRC formation [2, 3]. Cancer
cells are characterized by genome-wide hypomethylation
compared to normal cells leading to chromatin architec-
ture reorganization, genomic instability, loss of imprint-
ing, and activation of oncogenes. On the other hand,
local hypermethylation of CpG islands in the promoter
regions of certain genes contributes to their transcrip-
tional inactivation [4]. It was observed that among these
silenced genes are many well-characterized tumor sup-
pressor genes [3, 5]. Hypermethylation of tumor sup-
pressor genes is assumed to be functionally equivalent to
genetic loss-of-function mutations.
The reversibility of epigenetic modifications makes
them attractive targets for cancer treatment. The two
most extensively studied inhibitors of DNA methylation
are 5-azacytidine (5-aza-C) and 5-aza-2′-deoxycytidine
(5-aza-dC, decitabine), analogues of cytidine and 2′-
deoxycytidine, respectively, with a nitrogen atom re-
placing the carbon at the five position of the cytosine
base [6]. These compounds were first synthesized in the
1960s and were initially tested against acute myeloid
leukemia (AML). In 2004 (5-aza-C) and 2006 (5-aza-dC)
they were approved by the U.S. Food and Drug Adminis-
tration (FDA) for the treatment of patients with myelo-
dysplastic syndromes (MDS) [7, 8]. Once incorporated
into the genome during replication as regular nucleo-
tides, 5-aza-dC and 5-aza-C (from now referred to as 5-
azanucleosides) that replace cytosine targets for methyla-
tion form irreversible complexes with DNA (cytosine-5)
methyltransferases (DNMTs) leading to the depletion of
enzymes and passive loss of cytosine methylation with
each round of cell division. This results in DNA hypo-
methylation and reexpression of silenced tumor suppres-
sor genes, which were inactivated during carcinogenesis,
thereby restoring proliferation control and apoptosis
sensitivity [9]. It was also reported that 5-azanucleosides
induce selective and replication-independent degrad-
ation of DNMT1 by a proteasomal pathway [10].
Emerging data indicate that 5-azanucleosides are able to
sensitize cancer cells to the standard chemotherapeutic
agents and contribute to overcoming intrinsic or acquired
chemoresistance [11]. For instance, 5-azanucleosides have
been shown to increase the sensitivity of cancer cells to
cisplatin (prostate cancer, neuroblastoma), erlotinib and/
or gefitinib (AML, CRC), docetaxel (prostate cancer),
doxorubicin (breast cancer, neuroblastoma), etoposide
(neuroblastoma), and carboplatin (ovary cancer) [12–17].
In the present study, we demonstrated that DNA
demethylating agents (5-aza-dC, 5-aza-C) induce long-
lasting sensitization of CRC cells to inhibitors of topo-
isomerase I (irinotecan) and topoisomerase II (etoposide,
doxorubicin, mitoxantrone). The results of our study
may contribute to improving the effectiveness of current
treatments for CRC and possibly other cancers.
Methods
Cell culture and treatment
The human colorectal carcinoma cell lines HCT116,
DLD-1, DKs-8, and HT-29 were maintained in high-
glucose (4.5 g/l; POCH) DMEM (Hirszfeld Institute of
Immunology and Experimental Therapy, Polish Acad-
emy of Sciences) supplemented with 10% FBS (Gibco,
Thermo Fisher Scientific) and Antibiotic Antimycotic
Solution (Sigma-Aldrich). All cell lines were cultured at
37 °C in a humidified atmosphere of 5% CO2. The cells
were seeded at densities of 4 × 103 cells/0.1 ml
(0.32 cm2) (cell viability assay), 6 × 103–1 × 104 cells/
0.3 ml (0.7 cm2) (microscopic images), 2 × 104 cells/
0.5 ml (1.9 cm2) (flow cytometry), 1 × 105 cells/3 ml
(9.5 cm2) (long-term colony formation assay, serial
replating assay), 3.5 × 105 cells/3–4 ml (21 cm2) (West-
ern blotting). In short-term experiments, the cells were
treated either with 5-aza-dC (1 μM; Cayman Chemical)
or 5-aza-C (4 μM; Cayman Chemical) at the day of seed-
ing. After 2 days, the culture medium was changed and
the cells were treated either with 5-aza-dC or 5-aza-C
along either with irinotecan (5–75 μM; Cayman Chem-
ical), etoposide (5–50 μM; Sigma-Aldrich), doxorubicin
(0.05–0.9 μM; Cayman Chemical), or mitoxantrone
(0.05–1 μM; Cayman Chemical). Two or 3 days later, the
cells were collected for an appropriate assay. In long-
term colony formation assay and serial replating assay,
the cells were treated with 5-aza-dC (0.1 μM) 1 day
post-seeding. The next day, the cells were treated with eto-
poside (0.1–1 μM) and collected after two more days. In
Western blotting analyses of Akt, phospho-Akt, mTOR,
phospho-mTOR, p70S6K, and phospho-p70S6K expres-
sion, the cells were treated with 5-aza-dC (0.1–1 μM) 1 day
post-seeding. The cells were maintained in culture medium
without 5-aza-dC (the first passage after 3 days) and
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collected after six and twenty days. All compounds were
dissolved in DMSO (Sigma-Aldrich). Further dilutions were
made in culture medium immediately prior to experiment.
The final DMSO concentration never exceeded 0.75%.
Cell viability assay
Cell viability was assessed by CellTiter 96 AQueous One So-
lution Cell Proliferation Assay (Promega) according to the
manufacturer’s protocol. Each treatment within a single ex-
periment was performed in triplicate. Absorbance at
490 nm was recorded by a Wallac 1420 VICTOR2 plate
reader (PerkinElmer, Waltham, MA, USA). Data were nor-
malized to untreated control. The nature of the interactions
between 5-azanucleosides and topoisomerase inhibitors
was analyzed by the Chou-Talalay method [18, 19] using
CompuSyn software (ComboSyn, Paramus, NJ, USA).
Combination Index (CI) values for each drug combination
were determined as a quantitative measure of drug-drug
interaction. A CI value of < 0.9 indicates synergy, a CI value
of 0.9–1.1 indicates additive effect, and a CI value of > 1.1
indicates antagonism.
Microscopic images
The cells were fixed with 4% paraformaldehyde/PBS
(Sigma-Aldrich) for 30 min at 37 °C and washed three
times with PBS (with Ca2+ and Mg2+). The microscopic
images were taken using an Olympus IX-81 inverted
fluorescence microscope (Olympus, Tokyo, Japan) with a
10x objective and analyzed using cellSens software
(Olympus).
Flow cytometry
Both attached and detached cells were collected for
DNA fragmentation analyses. The cells were fixed with
ice-cold 70% ethanol (POCH) for 30 min at 4 °C and
stained with PI/PBS (50 μg/ml; Sigma-Aldrich) in the
presence of RNase A (0.02 mg/ml; Sigma-Aldrich) over-
night at 4 °C in the dark. In between steps, the cells were
washed with cold PBS (with Ca2+ and Mg2+) containing
2.5% FBS. Apoptosis was also assessed by Annexin V
Apoptosis Detection Kit (Santa Cruz Biotechnology) ac-
cording to the manufacturer’s protocol. Briefly, the cells
were stained with Annexin V-FITC (8 μg/ml) and PI
(5 μg/ml) for 15 min at RT in the dark. Data was ac-
quired on a FACSCalibur flow cytometer (Becton Dick-
inson, Franklin Lakes, NJ, USA) and analyzed using
Flowing Software 2.5.1 software (Perttu Terho, Turku,
Finland). Apoptosis was quantified as percentage of cells
with a hypodiploid DNA content (sub-G1 cell popula-
tion) and percentage of both Annexin V-positive and
Annexin V/PI-double-positive cells.
Long-term colony formation assay and serial replating
assay
The viable cells were counted using a hemacytometer
(trypan blue exclusion method) and seeded in duplicates
at a density of 5 × 102 cells/6 ml (21 cm2). The dishes
had been pre-coated with poly-L-lysine/PBS (0.001%;
Sigma-Aldrich) and washed twice with PBS (with Ca2+
and Mg2+). After 2 weeks, the colonies were fixed and
stained with 1% crystal violet/ethanol (Sigma-Aldrich),
documented with an Olympus Stylus SH-50 camera
(Olympus), and counted manually using ImageJ 1.47
software (National Institutes of Health, Bethesda, MD,
USA). In serial replating assay, several colonies from the
first plating were collected, cultured, and seeded in the
second plating. After 2 weeks, several colonies from the
second plating were collected, cultured, and seeded in
the third plating. The term plating efficiency (PE) indi-
cates the percentage of seeded cells that grow to form
colonies. The surviving fraction (SF) is calculated as a
ratio between PEs of treated and control cells multiplied
by 100.
Western blotting
Both attached and detached cells were collected for
H2A.X, γH2A.X, and CHOP expression analyses, whereas
only attached cells were taken for Akt, phospho-Akt,
mTOR, phospho-mTOR, p70S6K, and phospho-p70S6K
expression analyses. Whole cell lysates were prepared
using cold RIPA buffer [150 mM NaCl (POCH), 50 mM
Tris-HCl pH 8.0 (BioShop Canada), 1% NP-40 (Calbio-
chem), 0.5% sodium deoxycholate (Sigma-Aldrich), 1%
SDS (BioShop Canada)] supplemented with SigmaFAST
Protease Inhibitor Cocktail (Sigma-Aldrich) and Halt
Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific).
The cell lysates were then sonicated for 10 s at 100%
power using a Sonopuls HD 2070 ultrasonic homogenizer
(Bandelin, Berlin, Germany) and centrifuged at 10,000 x g
for 10 min at 4 °C to pellet cellular debris. Protein concen-
tration was determined by Pierce BCA Protein Assay Kit
(Thermo Fisher Scientific) according to the manufac-
turer’s protocol. Absorbance at 570 nm was recorded by a
Wallac 1420 VICTOR2 plate reader. Cell lysates with
Laemmli sample buffer [50 mM Tris-HCl pH 6.8, 10%
glycerol (BioShop Canada), 5% 2-mercaptoethanol
(Sigma-Aldrich), 2% SDS, 0.05% bromophenol blue (Bio-
Shop Canada)] were heated for 5 min at 95 °C, the pro-
teins were separated by SDS-PAGE as described by
Laemmli [20] using 8–15% resolving gels [SDS-PAGE
running buffer: 25 mM Tris, 192 mM glycine (BioShop
Canada), 0.1% SDS] and transferred (semi-dry transfer) to
PVDF membrane (0.45 μm pore size; Merck Millipore)
[transfer buffer: 25 mM Tris, 192 mM glycine, either 10%
or 20% methanol (POCH)]. In between steps, membranes
were washed with TBST [20 mM Tris, 150 mM NaCl,
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0.1% Tween 20 (BioShop Canada)]. Membranes were
blocked either with 1% casein [0.1 M Tris-HCl pH 8.0,
214 mM NaCl, 1% casein from bovine milk (Sigma-Al-
drich)] or 5% BSA/TBST (Sigma-Aldrich) for an hour at
RT or overnight at 4 °C and then incubated with primary
antibody overnight at 4 °C. After probing with HRP-
conjugated secondary antibody for 1 h at RT, proteins of
interest were detected using SuperSignal West Dura Ex-
tended Duration Substrate (Thermo Fisher Scientific). The
following antibodies were used in this study: anti-Akt
(1:1000, #4691; Cell Signaling Technology), anti-phospho-
Akt (1:1000, #4060; Cell Signaling Technology), anti-CHOP
(1:2000, #2895; Cell Signaling Technology), anti-H2A.X
(1:2000, #2595; Cell Signaling Technology), anti-γH2A.X
(1:2000, #9718; Cell Signaling Technology), anti-mTOR
(1:1000, #2983; Cell Signaling Technology), anti-phospho-
mTOR (1:1000, #2974; Cell Signaling Technology), anti-p
70S6K (1:1000, #2708; Cell Signaling Technology), anti-ph
ospho-p70S6K (1:1000, #9234; Cell Signaling Technology),
anti-actin/HRP (1:2000, #sc-1615; Santa Cruz Biotechnol-
ogy), anti-mouse/HRP (1:2500, #P0447; Dako, Agilent Tech-
nologies), anti-rabbit/HRP (1:2000–3000, #P0048; Dako,
Agilent Technologies).
Statistical analysis
Data are presented as means ± SD of results from at least
three independent experiments. Comparisons between
two groups (DNA demethylating agent treatment group
vs. combinatorial treatment group; topoisomerase inhibi-
tor treatment group vs. combinatorial treatment group)
were analyzed by two-tailed Student’s t-test. Significance
was assumed at p < 0.05. The Median Absolute Deviation
(MAD) test was employed to detect outliers. Asterisks in
the figures indicate that a combinatorial treatment group
was, at the same time, significantly different from a) DNA
demethylating agent treatment group alone; AND b) topo-
isomerase inhibitor treatment group alone.
Results
5-azanucleosides sensitize CRC cells to topoisomerase
inhibitors
In order to examine the mutual effects of DNA demethy-
lating agents and topoisomerase inhibitors, we analyzed
the viability of CRC cells after sequential treatments with
5-azanucleosides (5-aza-dC, 5-aza-C) and inhibitors of
topoisomerase I (irinotecan) or topoisomerase II (etopo-
side, doxorubicin, mitoxantrone). In our study, we used
the well-established CRC cell lines with different genetic
backgrounds: HCT116, DLD-1, HT-29 (Table 1). The cells
were treated with 5-aza-dC (1 μM) or 5-aza-C (4 μM) for
48 h followed by culture medium change and a second
treatment with 5-azanucleosides in combination with iri-
notecan (5–75 μM), etoposide (5–50 μM), doxorubicin
(0.05–0.9 μM), or mitoxantrone (0.05–1 μM) (Fig. 1a). 5-
Aza-dC and 5-aza-C alone decreased cell viability by an
average of 39.6 and 23.8% in HCT116 cells, 15.9 and
15.9% in DLD-1 cells, 8.1 and 16.0% in HT-29 cells, re-
spectively (Fig. 1b). In all tested cell lines, the combinator-
ial treatments reduced cell viability more effectively than
those of individual compounds at the same or even higher
concentrations (Fig. 1c, Fig. 2, Additional file 1: Table S1).
For instance, in HCT116 cells, the combinatorial
treatment with 5-aza-dC and 25 μM irinotecan was
more effective than 50 μM irinotecan used alone. All
the data, along with Combinatorial Index (CI) values
calculated by the Chou-Talalay method, are summa-
rized in Fig. 2 and presented in details in Additional
file 1: Table S1. They indicate that pretreatment with
5-azanucleosides was able to reinforce (in a synergis-
tic manner) the effectiveness of most tested topo-
isomerase inhibitors in all tested cell lines. More
specifically, 5-aza-dC and 5-aza-C pretreatment made
HCT116 and DLD-1 cells sensitive to all topoisomer-
ase inhibitors used, whereas 5-azanucleosides-treated
HT-29 cells had an increased sensitivity to irinotecan,
and in the case of 5-aza-dC, also to etoposide.
CRC driving mutations may influence cancer sus-
ceptibility to chemotherapy [21–23]. We examined
the relevance of a KRas mutation using the DLD-1/
DKs-8 isogenic cell line pair, where DLD-1 cells have
activating mutation in KRas (p.G13D) and the mu-
tant allele was disrupted in DKs-8 cells (Table 1).
The sequential treatment with 5-aza-dC and etopo-
side (Additional file 2: Figure S1), as well as other
combinations with 5-azanucleosides and topoisomer-
ase inhibitors (Fig. 2, Additional file 1: Table S1),
decreased DKs-8 cell viability compared to each
compound alone. Similar inhibitory effects were ob-
served in DLD-1 cells, which indicates the negligible
role of KRas mutational status in mutual actions of
5-azanucleosides and topoisomerase inhibitors in
CRC cells.




Oncogenes Tumor suppressor genes
KRAS BRAF TP53 MLH1
HCT116 G13D / wt wt / wt wt / wt S252* / S252* a
DLD-1 G13D / wt wt / wt S241F / wt (sil) wt / wt b
DKs-8 - / wt wt / wt S241F / wt (sil) wt / wt b
HT-29 wt / wt V600E / wt R273H / R273H wt (m) / wt c
Wt wild-type; sil silenced; m methylated; *nonsense mutation
aHCT116 cells are MMR-deficient due to mutations in MLH1 and mutS homolog
3 (MSH3) genes
bDLD-1 and DKs-8 cells are MMR-deficient due to mutation in mutS homolog 3
(MSH6) gene
cHT-29 cells are MMR-proficient
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Sequential treatments with 5-azanucleosides and topo-
isomerase inhibitors increase apoptosis in CRC cells, but
not through enhancement of DNA damage or ER stress
The described decreases in CRC cell viability after se-
quential treatments with 5-azanucleosides and topo-
isomerase inhibitors resulted from a reduction in cell
number (Fig. 3, data not shown). The combinatorial
treatments caused changes in cell morphology, e.g.
HCT116 cells were less elongated, whereas DLD-1 cells
were less densely packed than control and irinotecan- or
5-aza-dC-treated cells (Fig. 3). Furthermore, there were
more floating cells in culture medium. To examine
whether cell number reduction was attributed to en-
hanced cell death, we measured apoptosis-associated
Fig. 1 Pretreatment with 5-azanucleosides enhances the cytotoxicity of topoisomerase inhibitors in CRC cells. a Treatment scheme for short-term
experiments. b Cell viability of HCT116, DLD-1, and HT-29 cells after exposure to 1 μM 5-aza-dC (n≥ 14) or 4 μM 5-aza-C (n≥ 8) alone. c Cell viability of
HCT116 and DLD-1 cells after sequential treatments with 5-azanucleosides (1 μM 5-aza-dC or 4 μM 5-aza-C) and topoisomerase inhibitors (5–75 μM
irinotecan or 5–50 μM etoposide). Data are presented as means ± SD normalized to untreated control. *P < 0.05 compared with DNA demethylating
agent treatment group and topoisomerase inhibitor treatment group. Irin - irinotecan, eto - etoposide, dox - doxorubicin, mit - mitoxantrone
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DNA fragmentation by staining cells with propidium iodide
(PI). 5-Aza-dC alone increased the number of cells with a
hypodiploid DNA content to 23.6 ± 2.7% in HCT116 cells,
7.5 ± 0.4% in DLD-1 cells, and 2.0 ± 0.4% in HT-29 cells
(Fig. 4a, Additional file 3: Figure S2). The percentage of
apoptotic cells increased in a concentration-dependent
manner after etoposide treatment. Regardless of whether
the cells were resistant (HCT116) or sensitive (DLD-1) to
etoposide-induced apoptosis, pretreatment with 5-aza-dC
increased the number of apoptotic cells more effectively
than those of individual compounds at the same or even
higher concentrations. For instance, in HCT116 cells, the
combinatorial treatment with 5-aza-dC and 5 μM etoposide
was more effective than 50 μM etoposide used alone, show-
ing the potential of 5-azanucleosides to overcome resist-
ance to topoisomerase inhibitors in CRC cells. Similar
results were obtained with Annexin V-FITC/PI-double
staining (Fig. 4b, Additional file 4: Figure S3). On the other
hand, pretreatment with 5-aza-dC did not enhance
etoposide-induced DNA fragmentation in HT-29 cells
Fig. 2 Schematic summary of cell viability results. They demonstrate that pretreatment with 5-azanucleosides can reinforce the effectiveness of most tested
topoisomerase inhibitors in all tested CRC cell lines. Crossed hexagons indicate lack of synergy between a DNA demethylating agent and a topoisomerase
inhibitor (based on CI values calculated by the Chou-Talalay method). The number of independent experiments (n value) for each combination in each cell
line was given. All the data are presented in details in Additional file 1: Table S1. Irin - irinotecan, eto - etoposide, dox - doxorubicin, mit - mitoxantrone
Fig. 3 Combinatorial treatments cause changes in CRC cell morphology. Representative bright-field microscopic images (bar = 100 μm) of
HCT116 and DLD-1 cells after sequential treatments with 1 μM 5-aza-dC and 25-50 μM irinotecan. Figure 1a shows the treatment scheme
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(Fig. 4a, Additional file 3: Figure S2). Instead, a slight de-
crease in the number of cells with a hypodiploid DNA con-
tent was observed. These results were not consistent with
Annexin V-FITC/PI-double staining (Additional file 4: Fig-
ure S3), suggesting a non-apoptotic form of programmed
cell death in HT-29 cells.
5-Azanucleosides have previously been shown to be able
to induce DNA damage [24, 25]. In this regard, we investi-
gated whether sequential treatments with 5-azanucleosides
and topoisomerase inhibitors could cause DNA damage ac-
cumulation in CRC cells. Histone H2A.X phosphorylation
on serine 139 (γH2A.X) is a widely used marker of DNA
damage induced by DNA double-strand breaks formation.
As shown by Western blotting analysis, 5-aza-dC alone
only weakly induced γH2A.X in HCT116 cells (Fig. 4c).
Etoposide and irinotecan alone induced H2A.X phosphor-
ylation, but in combination with 5-aza-dC, γH2A.X levels
were decreased compared to etoposide or irinotecan alone.
Pretreatment with 5-aza-dC did not alter the levels of
etoposide- and irinotecan-induced γH2A.X in DLD-1 cells
(data not shown).
Since it was reported that zebularine, another cytidine
analogue and DNA methylation inhibitor, induces endo-
plasmic reticulum (ER) stress in HCT116 cells [26], we
examined the possibility that 5-azanucleosides sensitize
CRC cells to topoisomerase inhibitors by increasing ER
stress, thereby leading to cell death. As a marker of ER
stress-mediated apoptosis we used CCAAT/enhancer-
binding protein (C/EBP) homologous protein (CHOP).
As shown by Western blotting analysis, etoposide and
irinotecan alone, as well as their combinations with 5-
aza-dC, did not induce CHOP expression neither in
HCT116 (Fig. 4d) nor DLD-1 cells (data not shown).
Single treatments with 5-azanucleosides exert long-
lasting effects on HCT116 and DLD-1 cells
Having determined that 5-azanucleosides did not cause
considerable immediate toxic effects on CRC cells as
Fig. 4 Combinatorial treatments increase CRC cell apoptosis, but not through DNA damage or ER stress enhancement. a Apoptosis-associated DNA
fragmentation of HCT116, DLD-1, and HT-29 cells after sequential treatments with 1 μM 5-aza-dC and 5–50 μM etoposide (n= 3). Figure 1a shows the
treatment scheme. Data are presented as means ± SD. *P< 0.05 compared with DNA demethylating agent treatment group and topoisomerase inhibitor
treatment group. Representative histograms are presented in Additional file 3: Figure S2. b Representative Annexin V-FITC/PI-double staining histograms of
HCT116 cells after sequential treatments with 1 μM 5-aza-dC and 10 μM etoposide. Figure 1a shows the treatment scheme. More results are presented in
Additional file 4: Figure S3. c Representative immunoblot of γH2A.X (Ser139) expression from HCT116 cells sequentially treated with 1 μM 5-aza-dC and
25 μM etoposide/irinotecan (n= 3). H2A.X served as a loading control. d Representative immunoblot of CHOP expression from HCT116 cells sequentially
treated with 1 μM 5-aza-dC and 25 μM etoposide/irinotecan (n= 4). Actin served as a loading control. Figure 1a shows the treatment scheme. Jurkat cells
treated with 25 μM etoposide served as a positive control. C - control, eto - etoposide
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evaluated by analysis of cell viability (Fig. 1b, Additional
file 1: Table S1), apoptosis (Fig. 4a, b, Additional file 3:
Figure S2, Additional file 4: Figure S3), DNA damage
(Fig. 4c), and ER stress (Fig. 4d), we presumed that 5-
azanucleosides-induced sensitization to topoisomerase
inhibitors could be attributed to epigenetic alterations,
which can cause profound changes in cell homeostasis
for a longer period of time. In this regard, we analyzed
the viability of CRC cells at a later time point following
a single treatment with 5-azanucleosides. Indeed, in
DLD-1 cells, 5 days after 5-aza-dC treatment, cell viabil-
ity decreased only by 15.9%, whereas 13 days after 5-aza-
dC treatment, there was a 44.6% reduction in cell viabil-
ity (Fig. 5a). According to the literature reports [27], we
found that 5-azanucleosides reduce CRC proliferation
(Additional file 5: Figure S4). The morphology of 5-aza-
dC-treated cells was changing over time, reflecting the
deterioration of their condition, despite the fact that the
cells were regularly passaged (Fig. 5b). Similar effects
were observed in HCT116 cells (data not shown), show-
ing that 5-azanucleosides exert long-lasting effects on
CRC cells. Based on these observations, we investigated
whether a single exposure to 5-azanucleosides affects
phosphoinositide 3-kinase (PI3-kinase)/Akt signaling,
the main cellular pathway governing cell proliferation,
survival, metabolism, and epithelial-mesenchymal transi-
tion [28, 29]. For this purpose, we examined the
activation-associated phosphorylation of mammalian tar-
get of rapamycin (mTOR; Ser2481 - mainly associated
with activation of mTOR complex 2 (mTORC2)), Akt
(mTORC2-related phosphorylation of Ser473), and
p70S6K (mTORC1-related phosphorylation of Thr389).
DLD-1 cells were treated with 5-aza-dC (0.1–1 μM) and
maintained in drug-free culture medium (the first pas-
sage after 3 days) for the next 6 or 20 days. As shown by
Western blotting analysis, 5-aza-dC did not alter the ex-
pression of mTOR, Akt, and p70S6K proteins (Fig. 5c).
Similarly, the level of phospho-mTOR remained un-
changed 20 days after 5-aza-dC treatment. On the other
hand, there was a dose-dependent reduction in Akt
phosphorylation 20 days, but not 6 days, after 5-aza-dC
treatment, which was accompanied by a reduction of
downstream phospho-p70S6K.
Since single treatments with 5-azanucleosides cause
long-lasting effects on CRC cells, we investigated
whether 5-azanucleosides could sensitize CRC cells to
topoisomerase inhibitors for a longer period of time.
DLD-1 cells were treated with 5-aza-dC (1 μM) and
maintained in drug-free culture medium (the first pas-
sage after 3 days) followed by etoposide (5–50 μM)
treatment 10 days after 5-aza-dC addition (Fig. 6a). This
sequential treatment was still effective in reducing cell
viability compared to each compound alone (Fig. 6b).
Combinatorial treatments with 5-azanucleosides and
topoisomerase inhibitors reduce colony-forming ability of
HCT116 and DLD-1 cells
It has already been described that 5-azanucleosides de-
crease clonogenic potential of both solid tumor and
leukemia cell lines [30, 31], therefore we investigated
Fig. 5 5-Aza-dC exerts long-lasting effects on CRC cells. a Cell viability of DLD-1 cells 5 (n = 15) and 13 (n = 4) days after exposure to 1 μM 5-aza-
dC alone. Data are presented as means ± SD normalized to untreated control. b Representative bright-field microscopic images (bar = 100 μm) of
DLD-1 cells 22 days after exposure to 1 μM 5-aza-dC alone. c Representative immunoblots of phospho-mTOR (Ser2481), mTOR, phospho-Akt
(Ser473), Akt, phospho-p70S6K (Thr389), and p70S6K expression from DLD-1 cells 6 and 20 days after exposure to 0.1–1 μM 5-aza-dC alone (n ≥ 3).
Actin served as a loading control. D - days
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whether combinatorial DNA demethylating agents and
topoisomerase inhibitors treatments could impair CRC
cell colony-forming ability more effectively than those of
individual compounds. For this purpose, we performed
long-term colony formation assay. In DLD-1 cells, low-
dose etoposide (0.1–1 μM) alone reduced the surviving
fraction (SF) of cells in a concentration-dependent man-
ner, whereas low-dose 5-aza-dC (0.1 μM) alone caused a
21.5% reduction in cell clonogenicity (Fig. 7a). Higher con-
centrations of each compound (5 μM etoposide and 1 μM
5-aza-dC) resulted in complete inhibition of colony for-
mation (Additional file 6: Figure S5). However, the
sequential treatments with low doses of 5-aza-dC and
etoposide allowed to achieve similar strong inhibitory ef-
fect (Fig. 7a). The same inhibitory effects were observed in
HCT116 cells (data not shown).
Furthermore, we examined the clonogenic growth of
DLD-1 cells in serial replating assay, where the cells were
treated with compounds only once, 69 days (5-aza-dC)
and 68 days (etoposide) before the end of the experiment.
In the third plating, low-dose etoposide (0.5 μM) and low-
dose 5-aza-dC (0.1 μM) alone reduced the SF of cells by
19.2 and 15.7%, respectively (Fig. 7b). However, the com-
binatorial treatment caused a 56.3% reduction in cell clo-
nogenic/replating ability, and the colonies were much
smaller than either those formed by control or single-
agent-treated cells.
Discussion
The prognosis for patients with CRC, especially those with
metastatic CRC, remains poor. Considering the limited ef-
fectiveness of the current chemotherapy (mainly due to
both intrinsic and acquired drug resistance and dose-
limiting side effects), new efficient drug combinations are
urgently needed. In this study, we report that pretreatment
of CRC cells with 5-azanucleosides at clinically relevant
concentrations (0.1–1 μM 5-aza-dC and 4 μM 5-aza-C) en-
hances the anticancer effects of topoisomerase inhibitors,
such as irinotecan, a topoisomerase I inhibitor commonly
used in CRC treatment, as well as etoposide, doxorubicin,
and mitoxantrone, topoisomerase II inhibitors approved for
the treatment of other cancers. We found that prior expos-
ure to 5-azanucleosides sensitized CRC cells to topoisomer-
ase inhibitors, reducing cell viability and clonogenicity and
increasing programmed cell death more effectively than in-
dividual compounds at the same or even higher concentra-
tions. In our experimental settings, 5-azanucleosides did
not cause considerable immediate toxic effects on CRC
cells. HCT116 cells appeared to be the most sensitive of all
tested cell lines to 5-azanucleosides, which is consistent
with the previous report [32]. Topoisomerase inhibitors op-
erate by stabilizing the covalent DNA-topoisomerase cleav-
age complexes, thereby generating DNA single- and
double-strand breaks and ultimately leading to apoptosis
[33, 34]. The mechanism of the mutual action of 5-
azanucleosides and topoisomerase inhibitors still remains
unclear, but it involves neither DNA damage accumulation
nor ER stress augmentation, since we did not observe any
increases in H2A.X phosphorylation and CHOP expression
after combinatorial treatments. On the contrary, there was
even a decrease in γH2A.X levels in HCT116 cells, which
could possibly be explained by interference with H2A.X-as-
sociated DNA damage response pathway (for instance
γH2A.X formation and stability), as 5-azanucleosides are
obviously DNA affecting agents. This would lead to an in-
sufficient DNA damage response and repair after combina-
torial treatments and consequently increased cytotoxicity.
Furthermore, a decrease in γH2A.X levels in HCT116 cells
could be explained by reexpression of some epigenetically
silenced genes encoding DNA damage response and repair
proteins involved in homologous recombination (HR), non-
homologous end joining (NHEJ), and/or mismatch repair
(MMR) pathways [35, 36]. Interestingly, reexpression of
these proteins can also sensitize CRC cells to DNA dam-
aging agents. It was reported that 5-aza-dC-induced reex-
pression of Mlh1, a MMR protein, restores sensitivity of
SW48 CRC cells to 5-fluorouracil [37]. This reexpression
could be even more extensive after combinatorial treat-
ments, since topoisomerase II was shown to regulate the
maintenance of DNA methylation [38].
Fig. 6 Pretreatment with 5-aza-dC sensitizes CRC cells to etoposide for a longer period of time. a Treatment scheme. b Cell viability of DLD-1 cells
after sequential treatments with 1 μM 5-aza-dC and 5–50 μM etoposide (n = 4). Data are presented as means ± SD normalized to untreated con-
trol. Eto - etoposide
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Not all CRC cell lines used in this study responded to
the combinatorial treatments to the same extent, which
may partially result from differential metabolism of 5-
azanucleosides [39]. Yet the response to chemotherapy
is mainly determined by molecular features of cancer
cells [40]. Using the DLD-1/DKs-8 isogenic cell line pair,
we established that the presence of the KRas mutation
(p.G13D) is irrelevant in sequential 5-azanucleosides and
topoisomerase inhibitors treatments. It can be hypothe-
sized that the B-Raf mutation (p.V600E) may possibly
contribute to resistance of CRC cells to the combinator-
ial treatments, since B-Raf-mutated HT-29 cells ap-
peared to be the least sensitive of all tested cell lines to
the combinatorial treatments. However, this issue defin-
itely requires more research. Although it was reported
that p53 mutations can be a prerequisite for 5-aza-C-in-
duced sensitization to SN-38, an active metabolite of iri-
notecan [41], we found that 5-azanucleosides sensitize
both p53-mutated and wild-type (wt) p53-expressing
CRC cells to topoisomerase inhibitors (Table 1). On the
other hand, Plumb et al. showed that 5-aza-dC-induced
sensitization of human colon cancer xenografts to epiru-
bicin, a topoisomerase II inhibitor, depends on reexpres-
sion of MLH1 gene [42], while our results indicate that
5-azanucleosides induce sensitization to topoisomerase
inhibitors in MMR-deficient CRC cells (HCT116, DLD-
1; Table 1). Demethylation and reexpression of some
apoptosis-related genes was also pointed out to be re-
sponsible for 5-aza-dC-induced sensitization to irinote-
can [43]. In addition, genomic instability phenotypes
(such as chromosomal instability (CIN) and microsatel-
lite instability (MSI)) may possibly play a role in suscep-
tibility to sequential 5-azanucleosides and topoisomerase
inhibitors treatments, since HCT116 and DLD-1 cells
are characterized as CIN-negative and MSI, whereas
HT-29 cells as CIN-positive and microsatellite stable
(MSS) [44].
The most important outcome of our study is that a
single treatment with 5-azanucleosides is sufficient to in-
duce long-lasting sensitization to topoisomerase inhibi-
tors in CRC cells, effectively impairing their colony-
forming ability in a sequential setting. We found that
the combinatorial, but not separate, treatment with low
doses of 5-aza-dC (0.1 μM) and etoposide (0.5 μM)
caused a long-lasting (almost 70 days) reduction in clo-
nogenic/replating ability of DLD-1 cells. Therefore, the
sequential treatments with 5-azanucleosides and topo-
isomerase inhibitors have a therapeutic potential for
CRC treatment, because targeting a clonogenic/tumor-
initiating/stem cell-like subset of cancer cells is thought
to be essential for a successful cancer therapy [45]. Since
simultaneous treatments with 5-azanucleosides and
topoisomerase inhibitors were ineffective in CRC cells
(data not shown), epigenetic events are probably crucial
Fig. 7 Combinatorial treatments reduce colony-forming ability of CRC cells. a Long-term colony formation assay. On the left: representative images of
colonies formed by DLD-1 cells after sequential treatments with 0.1 μM 5-aza-dC and 0.1–1 μM etoposide. On the right: the surviving fraction (SF) of DLD-1
cells after sequential treatments with 0.1 μM 5-aza-dC and 0.1–1 μM etoposide (n= 3). b Serial replating assay. On the left: schematic representation of the
assay. The experiment ended on day 69 since the cells were treated with 0.1 μM 5-aza-dC. On the right: representative images of colonies formed by DLD-
1 cells in the third plating after sequential treatments with 0.1 μM 5-aza-dC and 0.5 μM etoposide. D - days
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in 5-azanucleosides-induced sensitization to topoisomer-
ase inhibitors. In this study, CRC cells were pretreated
with 5-azanucleosides before exposure to topoisomerase
inhibitors in order to allow the cells to divide at least
twice, which is required for passive loss of cytosine
methylation to become permanent [6]. The sensitization
to topoisomerase inhibitors may result from: i) reexpres-
sion of epigenetically silenced tumor suppressor genes
thereby restoring proliferation control and apoptosis
sensitivity; ii) relaxation of chromatin structure thereby
facilitating access of inhibitors to topoisomerases; iii) en-
hancement of genomic instability; and/or iv) loss of
DNMTs functions itself. Regardless of the direct mechan-
ism involved, we noted that 5-azanucleosides exert long-
lasting effects on CRC cells, reducing cell viability, prolifera-
tion, and changing cell morphology. In accordance with
these observations, we found that a single exposure to 5-
azanucleosides affects PI3-kinase/Akt signaling pathway.
There was a considerable dose-dependent reduction in Akt
phosphorylation 20 days after a single 5-aza-dC treatment.
Akt phosphorylation on Ser473 can be mediated by DNA-
dependent protein kinase (DNA-PK) or mTORC2, which
regulates cell metabolism and cytoskeleton organization
[46, 47]. The level of mTOR autophosphorylation
(associated with activation of mTORC2) remained un-
changed at that time point, which exclude its involvement
in attenuation of the PI3-kinase/Akt signaling. On the
other hand, it may result from 5-azanucleosides-induced
enhanced activity of PTEN, the major negative regulator
of PI3-kinase/Akt pathway. Interestingly, PTEN was re-
ported to contribute to sensitization of cancer cells to
various chemotherapeutic drugs [48, 49]. Decrease in Akt
phosphorylation was accompanied by a profound reduc-
tion of downstream phospho-p70S6K, suggesting an im-
pairment of mTORC1 activity. Disturbances in both
mTORC1 and mTORC2 signaling pathways may possibly
contribute to the observed changes in CRC cell morph-
ology and decreases in cell viability and proliferation after
5-azanucleosides treatment.
Conclusions
Taken together, we show that pretreatment of CRC cells
with 5-azanucleosides potentiates the anticancer effects
of topoisomerase inhibitors, suggesting that the combin-
ation of these two drug classes represents a promising
therapeutic approach for the treatment of CRC and pos-
sibly other cancers. Importantly, prior exposure to 5-
azanucleosides could potentially reduce topoisomerase
inhibitors dosing and therefore decrease their side ef-
fects, such as myelosuppression. Similarly, it has been
reported that 5-aza-C potentiates anticancer activity of
cisplatin and, at the same time, attenuates the cisplatin-
induced nephrotoxicity [50]. Thus, our findings strongly
encourage future in vivo studies on combinatorial use of
DNA demethylating agents and topoisomerase inhibitors.
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Additional file 1: Table S1. Comprehensive summary of CRC cell
viability results after sequential treatments with 5-azanucleosides and
topoisomerase inhibitors. Data are presented as means ± SD normalized
to untreated control. *P < 0.05 compared with DNA demethylating agent
treatment group and topoisomerase inhibitor treatment group. Combina-
torial Index (CI) values for each drug combination were determined. N/D
- no data. (PDF 45.3 kb)
Additional file 2: Figure S1. Pretreatment with 5-aza-dC enhances the
cytotoxicity of etoposide in DKs-8 cells. Cell viability of DKs-8 cells after
sequential treatments with 1 μM 5-aza-dC and 5-50 μM etoposide. Figure 1a
shows the treatment scheme. Data are presented as means ± SD normalized
to untreated control. *P < 0.05 compared with DNA demethylating agent
treatment group and topoisomerase inhibitor treatment group. (PDF 33.6 kb)
Additional file 3: Figure S2. Combinatorial treatments increase
apoptosis-associated DNA fragmentation in CRC cells. Representative his-
tograms of HCT116, DLD-1, and HT-29 cells after sequential treatments
with 1 μM 5-aza-dC and 5-50 μM etoposide. Figure 1a shows the treatment
scheme. (PDF 208 kb)
Additional file 4: Figure S3. Combinatorial treatments increase CRC cell
apoptosis. Annexin V-FITC/PI-double staining of HCT116, DLD-1, and HT-29
cells after sequential treatments with 1 μM 5-aza-dC and 25 μM etoposide
(n = 3). Figure 1a shows the treatment scheme. Data are presented as
means ± SD. *P < 0.05 compared with DNA demethylating agent treatment
group and topoisomerase inhibitor treatment group. (PDF 177 kb)
Additional file 5: Figure S4. 5-Aza-dC reduces CRC cell proliferation.
Cell proliferation of DLD-1 cells within 7 days of exposure to 1 μM 5-aza-
dC alone. Green histograms: tested cells; white histograms: unstained
cells; grey histograms: the cells stained on the day of analysis. The per-
centage of cells in gates represents non-proliferating cells. Cell prolifera-
tion was assessed by CellTrace Far Red Cell Proliferation Kit (Molecular
Probes, Thermo Fisher Scientific) according to the manufacturer’s proto-
col. Briefly, the cells were stained with CellTrace Far Red (1 μM) for
20 min at 37 °C. Data was acquired on a FACSCalibur flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed using Flowing
Software 2.5.1 software (Perttu Terho, Turku, Finland). (PDF 46 kb)
Additional file 6: Figure S5. Etoposide or 5-aza-dC treatment reduces
colony-forming ability of CRC cells. Representative images of DLD-1 colonies
after treatment with 5 μM etoposide or 1 μM 5-aza-dC. (PDF 927 kb)
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